Mannkind, Game-Chancer in Sachen Diabetik? (Seite 135)
eröffnet am 11.01.11 13:02:26 von
neuester Beitrag 03.04.24 20:06:55 von
neuester Beitrag 03.04.24 20:06:55 von
Beiträge: 6.825
ID: 1.162.683
ID: 1.162.683
Aufrufe heute: 0
Gesamt: 593.809
Gesamt: 593.809
Aktive User: 0
ISIN: US56400P7069 · WKN: A2DMZL · Symbol: MNKD
4,2300
USD
+1,20 %
+0,0500 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 7,3500 | +43,84 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,110 | -13,44 | |
| 8,2200 | -13,47 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Den habe ich!
Antwort auf Beitrag Nr.: 61.064.707 von price-of-success am 19.07.19 13:47:08....man braucht einen langen atem
voila
die 800 TRX in Reichweite
TRX 770
rest auf stocktwits zu finden
die 800 TRX in Reichweite
TRX 770
rest auf stocktwits zu finden
Mannkind zahlt Schulden zurück:
MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants
GlobeNewswire•July 18, 2019
WESTLAKE VILLAGE, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0 million and the repurchase of a warrant to purchase approximately 3.3 million shares of common stock.
The Company repaid approximately $4.0 million of the Deerfield Financing Obligation that was due July 18, 2019 with $2.42 million in cash and by issuing 1,514,423 shares of the Company’s common stock valued at $1.04 per share, the closing price of the Company’s common stock on July 17, 2019 as reported on the Nasdaq Stock Market.
The Company also repurchased a warrant to acquire approximately 3.3 million shares of the Company’s common stock from the holder thereof for approximately $433,000. Following the repurchase, the warrant was cancelled and is no longer issued and outstanding.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
MannKind Contact:
Rose Alinaya
Investor Relations
818-661-5000
ir@mannkindcorp.com
MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants
GlobeNewswire•July 18, 2019
WESTLAKE VILLAGE, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0 million and the repurchase of a warrant to purchase approximately 3.3 million shares of common stock.
The Company repaid approximately $4.0 million of the Deerfield Financing Obligation that was due July 18, 2019 with $2.42 million in cash and by issuing 1,514,423 shares of the Company’s common stock valued at $1.04 per share, the closing price of the Company’s common stock on July 17, 2019 as reported on the Nasdaq Stock Market.
The Company also repurchased a warrant to acquire approximately 3.3 million shares of the Company’s common stock from the holder thereof for approximately $433,000. Following the repurchase, the warrant was cancelled and is no longer issued and outstanding.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
MannKind Contact:
Rose Alinaya
Investor Relations
818-661-5000
ir@mannkindcorp.com
Antwort auf Beitrag Nr.: 61.013.294 von Magnetfeldfredy am 12.07.19 15:24:42...wie waren denn die verkaufszahlen letzter Woche?
Trading Spotlight
Interessante Pressemeldung von gestern, ich glaube bald wird das zweite Molekül auslizensiert, epinephrine
, die Fertigungsanlage steht, der Partner kann kommen:
MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules
GlobeNewswire•July 11, 2019
WESTLAKE VILLAGE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.
“This expansion will allow us to utilize more fully the capacity of our world class, FDA-approved manufacturing facility for dry powder inhalation products. We are also pursuing opportunities to utilize our lyophilization capacity to fulfill the needs of our industry and drug development partners," stated Joe Kocinsky, Chief Technology Officer of MannKind.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
, die Fertigungsanlage steht, der Partner kann kommen:MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules
GlobeNewswire•July 11, 2019
WESTLAKE VILLAGE, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.
“This expansion will allow us to utilize more fully the capacity of our world class, FDA-approved manufacturing facility for dry powder inhalation products. We are also pursuing opportunities to utilize our lyophilization capacity to fulfill the needs of our industry and drug development partners," stated Joe Kocinsky, Chief Technology Officer of MannKind.
About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Antwort auf Beitrag Nr.: 60.948.547 von questionmark am 03.07.19 18:34:45...mir fällt da noch medtronic ein.
die stellen Insulinpumpen her, als Erweiterung für dessen Geschäftsmodell wäre es genau das richtige um sich Mannkind zu schnappen.
gruss
die stellen Insulinpumpen her, als Erweiterung für dessen Geschäftsmodell wäre es genau das richtige um sich Mannkind zu schnappen.
gruss
Antwort auf Beitrag Nr.: 60.947.704 von sir1 am 03.07.19 17:14:08Man könnte auch argumentieren, dass NN oder Lilly nicht zugreifen heißt, dass keiner daran interessiert ist. Kann noch Jahre dauern, oder sich nie durchsetzen.
Wann war noch das FDA approval? ....
Wann war noch das FDA approval? ....
Antwort auf Beitrag Nr.: 60.923.161 von pegasusorion am 30.06.19 16:34:20Ich verstehe es auch nicht, wieso Novo Nordisk nicht Mannkind übernimmt.
Die zahlen das doch aus der Portokasse und sind Marktführer.
Für wäre das eine Riesenvorsprung zur Konkurrenz.
...mal sehen.....viele Interessenten wird es nicht geben, aber derjenige der Mannkind schluckt,
hat einen einen grossen Vorsprung und das entsprechende Vertriebsnetz um in kurzer Zeit richtig einen Block Buster draus zu machen....
meine persönliche Einschätzung.
Die zahlen das doch aus der Portokasse und sind Marktführer.
Für wäre das eine Riesenvorsprung zur Konkurrenz.
...mal sehen.....viele Interessenten wird es nicht geben, aber derjenige der Mannkind schluckt,
hat einen einen grossen Vorsprung und das entsprechende Vertriebsnetz um in kurzer Zeit richtig einen Block Buster draus zu machen....
meine persönliche Einschätzung.
Antwort auf Beitrag Nr.: 60.923.161 von pegasusorion am 30.06.19 16:34:201,13 Mio. USD im Vergleich zu 1,09 Mio. USD. Der wöchentliche Bruttoumsatz beginnt regelmäßiger über 1 Mio. USD zu steigen. JMHO.
Durchsuchen
Mannkind, Game-Chancer in Sachen Diabetik?
